International Clinical Trial: Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07821606) titled 'Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Hansoh BioMedical R&D Company

Condition: Platinum-sensitive Recurrent Ovarian Cancer

Intervention: Drug: HS-20089+Bevacizumab Drug: Dose 2:arboplatin+Paclitaxel+Bevacizumab Drug: Dose 3:arboplatin+Gemcitabine+Bevacizumab

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: November 1, 2026

Target Sampl...